title: Does increased urinary interleukin-1 receptor antagonist/interleukin-1beta ratio indicate good prognosis in renal transplant recipients?
abstract: BACKGROUND
  Interleukin-1 (IL-1) is produced by activated monocytes/macrophages; highly increased amounts of IL-1 have been found in renal tissue in acute rejection of renal grafts. The endogenous inhibitor of IL-1, interleukin-1 receptor antagonist (IL-1ra), is produced in many cells in response to the same stimulus as IL-1. There is some evidence that the balance between IL-1 and IL-1ra is important in the regulation of inflammatory responses. In many inflammatory diseases in both humans and animals, a high concentration of endogenous IL-1ra or administration of exogenous IL-1ra has been shown to relate to shorter recovery time or to reduced mortality.
  
  
  METHODS
  We measured the urinary excretion of IL-1ra and IL-1beta during the first 3-6 posttransplant weeks in 23 patients with acute rejection (69 24-hr urine samples) and in 17 patients with stable graft function (51 24-hr urine samples) and expressed the results as cytokine/creatinine ratios.
  
  
  RESULTS
  Within the follow-up time, patients with rejection had higher urinary IL-1beta/creatinine (ng/mmol) ratios (median 5.0 vs. 2.7; P<0.005), lower IL-1ra/creatinine (ng/mmol) ratios (median 18.1 vs. 34.2; P<0.1), and consequently lower IL-1ra/IL-1beta ratios (median 3.6 vs. 20.3, P<0.005), compared with patients without rejection. In rejecting patients, IL-1ra/creatinine was constantly low and decreased even further during acute rejection, whereas IL-1beta/creatinine ratios increased from a median prerejection value of 3.5 (range not measurable to 9.0) to a median value of 8.1 (P<0.0005) (range 1.6 to 18.3) during rejection.
  
  
  CONCLUSIONS
  These results suggest that patients who produce high amounts of IL-1ra in relation to IL-1beta are less prone to acute allograft rejection than patients with low IL-1ra/IL-1beta ratios.
authors.affiliation: Department of Medicine, Helsinki University Central Hospital, Finland.
authors.forename: A M
authors.initials: AM
authors.lastname: Teppo
authors.forename: E
authors.initials: E
authors.lastname: Honkanen
authors.forename: J
authors.initials: J
authors.lastname: Ahonen
authors.forename: C
authors.initials: C
authors.lastname: Grönhagen-Riska
mesh_terms: D000328:Adult; D002097:C-Reactive Protein / Q000032:analysis; D002940:Circadian Rhythm / Q000502:physiology; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000652:urine; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000652:urine*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011379:Prognosis; D012016:Reference Values; D012795:Sialoglycoproteins / Q000652:urine*
chemical_list: C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D012795:Sialoglycoproteins; D002097:C-Reactive Protein; D003404:Creatinine